|
Market Closed -
OTC Markets
03:58:20 27/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.0251 USD | -16.33% |
|
-28.29% | -3.46% |
| 05-19 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
Company Valuation: Adaptimmune Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 834.3 | 585.8 | 239.2 | 180.1 | 137.8 | 6.891 |
| Change | - | -29.79% | -59.17% | -24.7% | -23.47% | -95% |
| Enterprise Value (EV) 1 | 489.8 | 241.7 | 57.66 | 58.4 | 60.45 | -4.978 |
| Change | - | -50.66% | -76.14% | 1.29% | 3.5% | -108.23% |
| P/E | -5.9x | -3.7x | -1.42x | -1.4x | -1.8x | 0.33x |
| PBR | 2.45x | 2.85x | 2.93x | 4.56x | 11.6x | 0.22x |
| PEG | - | -0.3x | -1.23x | 0x | 0x | -0x |
| Capitalization / Revenue | 211x | 95.3x | 8.81x | 2.99x | 0.77x | 1.16x |
| EV / Revenue | 124x | 39.3x | 2.12x | 0.97x | 0.34x | -0.84x |
| EV / EBITDA | -3.89x | -1.55x | -0.37x | -0.46x | -1.47x | 0.09x |
| EV / EBIT | -3.67x | -1.49x | -0.36x | -0.42x | -1.15x | 0.08x |
| EV / FCF | -7.8x | -3.22x | -0.53x | -0.79x | 27.8x | 0.08x |
| FCF Yield | -12.8% | -31% | -190% | -126% | 3.59% | 1,238% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.9132 | -1.015 | -1.026 | -0.5663 | -0.3 | 0.0789 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3.958 | 6.149 | 27.15 | 60.28 | 178 | 5.924 |
| EBITDA 1 | -125.8 | -155.7 | -155.6 | -128.2 | -41.18 | -57.49 |
| EBIT 1 | -133.4 | -162.2 | -161.7 | -138 | -52.41 | -64.12 |
| Net income 1 | -130.1 | -158.1 | -165.5 | -113.9 | -70.81 | 25.21 |
| Net Debt 1 | -344.5 | -344.1 | -181.5 | -121.7 | -77.4 | -11.87 |
| Reference price 2 | 5.3900 | 3.7500 | 1.4600 | 0.7930 | 0.5387 | 0.0260 |
| Nbr of stocks (in thousands) | 154,779 | 156,204 | 163,829 | 227,122 | 255,883 | 265,052 |
| Announcement Date | 25/2/21 | 14/3/22 | 6/3/23 | 6/3/24 | 24/3/25 | 19/5/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.65M | |
| 37.58x | 13.15x | 27.92x | 0.53% | 1,140B | |
| 38.98x | 6.55x | 18.43x | 2% | 641B | |
| 37.5x | 8.41x | 17.39x | 2.4% | 507B | |
| 21.33x | 5.19x | 12.91x | 2.53% | 383B | |
| 102.5x | 5.75x | 24.67x | 2.42% | 347B | |
| 21.61x | 5.64x | 13.85x | 2.84% | 293B | |
| 22.44x | 4.53x | 12.94x | 1.95% | 266B | |
| 28.21x | 7.23x | 12.94x | 2.27% | 240B | |
| -46.25x | 7.08x | 27.47x | 2.08% | 197B | |
| Average | 29.32x | 7.06x | 18.73x | 2.11% | 401.38B | |
| Weighted average by Cap. | 35.01x | 8.33x | 20.42x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADAPY Stock
- Valuation Adaptimmune Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
